Alveron Pharma is developing a unique coagulation
platform technology with the world's first
cyclodextrin-based anticoagulant reversal drug.
platform technology with the world's first
cyclodextrin-based anticoagulant reversal drug.
Total raised: $5.29M
Investors 1
| Date | Name | Website |
| - | Waterman V... | watermanve... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 09.12.2024 | Seed | $5.29M | - |
Mentions in press and media 4
| Date | Title | Description |
| 11.12.2024 | Alveron Pharma Secures €5 Million to Tackle Intracranial Hemorrhage | In the world of pharmaceuticals, every second counts. Alveron Pharma, a Dutch biotech firm, is racing against time. The company recently closed a €5 million seed extension financing round, a crucial step in its mission to combat intracrania... |
| 09.12.2024 | Alveron Pharma: €5 Million (Seed Extension) Raised To Advance Intracranial Haemorrhage Therapy | Alveron Pharma announced the closing of a €5 million Series Seed extension financing (about $5.28 million) to advance the development of its innovative drug, OKL-1111, to treat intracranial hemorrhage (ICH). And the syndicate is led by Broa... |
| 09.12.2024 | Alveron Pharma Closes €5M Seed Extension Financing | Alveron Pharma, a Nijmegen, the Netherlands-based company advancing a synthetic anticoagulant and platelet inhibitor reversal agent, raised €5M in Seed extension funding. The round was led by Broadview Ventures with participation from Sanqu... |
| - | Alveron Pharma | “HOME | Alveron Pharma” |